As the field of oncology evolves, we need to shift away from traditional binary “yes-no” biomarkers to a more nuanced, spatial understanding of tumor biology. This approach will allow for more personalized treatment plans that are tailored to the unique characteristics of each patient’s tumor.
Antibody-drug conjugates (ADCs) are designed to deliver precise blows to cancer cells, much like a well-aimed strike. However, the real power of these therapies lies not only in their direct targeted impact but in the broader “blast radius” and “bystander killing” effect they generate within the tumor microenvironment.
To fully understand and control this effect, we need to go beyond traditional diagnostic pathology methods. Spatial artificial intelligence (AI), which maps, analyzes, and interprets the complex cellular interactions in a patient’s tumor biopsy, and spatial biomarkers are crucial for guiding these powerful therapies and ensuring they achieve their intended results.
